Successful Adjuvant Treatment of Recalcitrant Mucous Membrane Pemphigoid with Anti-CD20 Antibody Rituximab
July 2007 | Volume 6 | Issue 7 | Case Reports | 731 | Copyright © July 2007
Josephine A. Taverna MD, Adam Lerner MD, Jag Bhawan MD, Marie-France Demierre MD FRCPC
Rituximab is a humanized monoclonal antibody directed against CD20-positive B cells and originally developed for the treatment
of non-Hodgkins lymphoma. We report a case of severe mucous membrane pemphigoid responsive to rituximab infusions.
The clinical presentation, etiology, and management options for mucous membrane pemphigoid are also discussed.